By continuing to use this site you consent to the use of cookies on your device as described in our
Cookie Policy unless you have disabled them. You can change your Cookie Settings at any time but parts of our site will not function correctly without them.

Scientists have developed a vaccine candidate for the Zika virus which they say successfully protected both mice and monkeys from the infection that causes brain deformations in human babies.

Demonstrating the effectiveness of the vaccine candidate in monkeys (non-human primates) is an important milestone because it typically predicts the vaccine will work in humans, enabling further clinical development, researchers at the University of Hawaii in the US said.

There is no treatment or cure for Zika virus infection nor is any vaccine currently approved for public use.

The proposed vaccine, reported in the journals Frontiers in Immunology and mSphere, uses a protein of the Zika virus, produced in insect cells.

"We believe our vaccine candidate shows much promise particularly as it showed to require only two immunisations given three weeks apart and is a potentially safer alternative to other candidates already in clinical trials," said Axel Lehrer, assistant professor at University of Hawaii.

The vaccine may be safer that other candidate vaccines, especially keeping in mind that pregnant women constitute a significant part of the target population for a Zika vaccine.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)